---
title: "Key facts: Jazz Pharmaceuticals (JAZZ) Q2 Ziihera $15.4M; PDUFA Aug 25"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294782817.md"
description: "Jazz Pharmaceuticals reported $15.4M Q2 sales for Ziihera in biliary tract cancer and received FDA Priority Review for its HER2+ gastroesophageal sBLA, with a PDUFA date of August 25, 2026. Revenue growth was driven by Xywav, Epidiolex, and oncology launches. Ahead of earnings, analysts project EPS of $6.18 and revenue of $1.12B, with a median 12-month target price of $275. Additionally, Jazz plans to file an FDA labeling supplement in Q3 to remove Zepzelca's second-line indication."
datetime: "2026-08-04T07:14:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294782817.md)
  - [en](https://longbridge.com/en/news/294782817.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294782817.md)
generator: "portal-rs"
---

# Key facts: Jazz Pharmaceuticals (JAZZ) Q2 Ziihera $15.4M; PDUFA Aug 25

-   Jazz Pharmaceuticals (JAZZ) posted $15.4M Q2 2026 sales for Ziihera in biliary tract cancer. FDA granted Priority Review for HER2+ first‑line gastroesophageal sBLA; PDUFA date Aug 25, 2026. TradingView
-   Jazz Pharmaceuticals (JAZZ) revenue grew driven by Xywav, Epidiolex and oncology launches; Xywav volumes and active patient count rose while high-sodium Xyrem volumes fell due to generics. TradingView
-   Jazz Pharmaceuticals (JAZZ) ahead of earnings: mean EPS $6.18, revenue $1.12B; mean EPS rose ~3.7% in 3 months; consensus: 19 buy/strong buy, 1 hold; median 12‑mo target $275. Reuters
-   Jazz Pharmaceuticals (JAZZ) will file an FDA labeling supplement in Q3 to remove Zepzelca's second‑line indication; the first‑line maintenance indication will stay unchanged. Reuters

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.

### Related Stocks

- [JAZZ.US](https://longbridge.com/en/quote/JAZZ.US.md)

## Related News & Research

- [Jazz Pharmaceuticals (JAZZ) Could Be 13% Undervalued On FDA Approval Of Ziihera](https://longbridge.com/en/news/297431759.md)
- [Jazz says FDA approves Ziihera combos for first-line HER2+ advanced gastroesophageal cancer](https://longbridge.com/en/news/297497068.md)
- [These Analysts Increase Their Forecasts On Jazz Pharmaceuticals](https://longbridge.com/en/news/297066303.md)
- [JAZZ: FDA approved Ziihera regimens for first-line HER2+ GEA, setting a new standard of care](https://longbridge.com/en/news/296933637.md)
- [Jazz Pharmaceuticals highlights Ziihera launch, targets $3-$5 billion zanidatamab peak sales opportunity](https://longbridge.com/en/news/297016685.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**